期刊文献+

经皮射频治疗肝脏恶性肿瘤114例临床分析 被引量:13

Percutaneous radiofrequency ablation therapy for hepatic malignancies in 114 patients
在线阅读 下载PDF
导出
摘要 目的评价经皮射频(PRFA)治疗肝脏恶性肿瘤的效果、安全性和价值。方法应用RF-2000射频仪和10电极LeVeen射频针经皮穿刺治疗肝脏恶性肿瘤114例153个病灶,B超引导监测,局麻配合全身镇痛处理,对于肿瘤病灶>2.5 cm者进行分层多点叠合毁损,>5.0 cm或多发者配合肝动脉导管化疗栓塞术,随访观察治疗效果、并发症和生存情况。结果PRFA成功率100%,并发症率6.14%(7/114),无相关死亡。3月、6月、1年、2年、3年生存率分别为100.00%(114/114),97.40%(111/114),74.60%(85/114),59.40%(41/69)和36.80%(7/19)。结论PRFA治疗肝脏恶性肿瘤具有微创、有效、简捷、实用、可重复、相对安全等优势,对各种类型不同大小的肝脏恶性肿瘤均有疗效。 Objective: To assess the local treatment efficacy and safety of percutaneous radiofrequency ablation (PRFA) therapy for hepatic malignancies. Methods: 153 malignant tumors of the liver in 114 patients were ablated by using RF-2000 generator and 10-needle LeVeen electrode percutaneously guided by B-ultrasound under sedation and local anesthesia. Lesions larger than 2.5 cm in diameter were treated by multiple overlapping ablations encompassing the entire lesion as well as a rim of normal liver tissue (approximately 1.0 cm), and the malignant tumors that were larger than 5.0 cm in size or multifocal were treated by in combination with transcatheter arterial chemoembolization (TACE). Results: The procedures were performed successfully in all cases. The post-PRFA complication rate was 6.14%, without PRFA-related death. The patients' survival rates were 100.00% (114/114) at 3 months, 97.40% (111/114) at 6 months, 74.60% (85/114) at 1 year, 59.40% (41/69) at 2 years, and 36.80% (7/19) at 3 years. Conclusions: It shows that with the advantages of being mini-invasive, simple and safe, PRFA is an effectie therapy in the comprehensive treatment of hepatic malignancies.
机构地区 解放军第
出处 《中国现代医学杂志》 CAS CSCD 2004年第20期129-131,135,共4页 China Journal of Modern Medicine
关键词 肝脏恶性肿瘤 射频治疗 超声引导 hepatic malignancies radiofrequency ablation therapy ultrasonography guidance
  • 相关文献

参考文献8

二级参考文献40

  • 1吴孟超.肝海绵状血管瘤.黄家驷外科学,第6版[M].北京:人民卫生出版社,1999.1234-1235.
  • 2[1]Rhim H, Dodd Ⅲ GD.Radiofrequency thermal ablation of liver tumors.J Clin Ultrasound, 1999;27:221~229
  • 3[3]Llovet JM, Sala M, Bruix J.Nonsurgical treatment of hepatocellular carcinoma. Liver Transplantation, 2000;6:S11~S15
  • 4[4]Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation ofhepatoce llular cancer in 110 patients with cirrhosis.Ann Surg, 2000;232:381~391
  • 5[5]Wood TF, Rose DM, Chung M, et al.Radiofrequency ablation of 231 unresectable hepatic tumors: indications, imitations and complications.Ann Surg Oncol, 2000;7:593~600
  • 6[6]So lbiati L, Goldberg SN, Ierace I, et al.Hepatic metastases percutane ous radio-frequency ablation with cooled-tip electrodes.Radiology, 199 7;205:367~373
  • 7[7]Solbiati L, Ierace T, Goldberg SN, et al.Percutaneous US-guided radio-frequency tissue ablation of liver metastases:treatment and follow-up in 16 pa tients. Radiology,1997;202:195~203
  • 8[8]Goldberg SN, Stein MC, Gazelle GS, et al. Percutaneous radiofrequency tissue ablation:optimization of pulsed-radiofrequency technique to incre ase coagulation necrosis.J Vasc Interv Radio 1, 1999;10:907~916
  • 9[9]Steiner P, Botnar R, Goldberg SN, et al.Monitoring of radio-frequency tissue ablation in an intervenfional MR enviroment:preliminary ex vivo and in vivo results. Invest Radio 1, 1997;32:671~678
  • 10[10]Daly B, Templeton PA.Real-time CT fluoroscopy:evaluation of an interventional tool. Radiology, 1999;211:309~315

共引文献142

同被引文献82

引证文献13

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部